Send to

Choose Destination
Bioimpacts. 2019;9(3):123-127. doi: 10.15171/bi.2019.16. Epub 2019 Mar 8.

Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates.

Author information

Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, 51656-65811, Iran.
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.


Despite rapid advances in diagnostic and treatment approaches, the overall survival rate of cancer has not been improved. Colorectal cancer (CRC) is recognized as the third leading cause of neoplasm-related deaths worldwide, in large part due to its considerable metastasis and drug resistance. For developing new anticancer strategies, rapid progression of multimodal nanomedicines and nanoconjugates has provided promising treatment modalities for effective therapy of cancer. The limitations of cancer chemotherapy might be overcome through the use of such nanosized therapeutics, including nanoconjugates of monoclonal antibodies (mAbs) along with drugs and organic/inorganic nanoparticles. CRC cells express various molecular markers against which mAbs can be designed and used as targeting/therapeutic agents. This editorial highlights the importance of such targeted nanosystems against CRC.


Colorectal cancer; Monoclonal antibodies; Nanocarrier; Nanoconjugates; Nanomedicines; Targeted therapy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center